Discovery of a Prenylated Flavonol Derivative as a Pin1 Inhibitor to Suppress Hepatocellular Carcinoma by Modulating MicroRNA Biogenesis
作者:Yuanyuan Zheng、Wenchen Pu、Jiao Li、Xianyan Shen、Qiang Zhou、Xin Fan、Sheng-Yong Yang、Yamei Yu、Qiang Chen、Chun Wang、Xin Wu、Yong Peng
DOI:10.1002/asia.201801461
日期:2019.1.4
isomerase Pin1 plays a crucial role in the development of human cancers. Recently, we have disclosed that Pin1 regulates the biogenesis of miRNA, which is aberrantly expressed in HCC and promotes HCC progression, indicating the therapeutic role of Pin1 in HCC therapy. Here, 7‐(benzyloxy)‐3,5‐dihydroxy‐2‐(4‐methoxyphenyl)‐8‐(3‐methylbut‐2‐en‐1‐yl)‐4H‐chromen‐4‐one (AF‐39) was identified as a novel Pin1
肽脯氨酰顺-反异构酶中Pin1在人类癌症的发展至关重要的作用。最近,我们披露了Pin1调节miRNA的生物发生,miRNA在HCC中异常表达并促进HCC进展,表明Pin1在HCC治疗中的治疗作用。在此,7-(苄氧基)-3,5-二羟基-2-(4-甲氧基苯基)-8-(3-甲基丁-2-烯-1-基)-4H-铬-4--1(AF-39)被鉴定为新型的Pin1抑制剂。生化试验表明,AF-39有效抑制中Pin1活性,其IC 50的1.008μ值米,并且还显示中肽基脯氨酰异构酶对中Pin1高选择性。此外,AF‐39以剂量和时间依赖性方式显着抑制HCC细胞的细胞增殖。从机制上讲,AF-39调节XPO5的亚细胞分布并增加HCC细胞中miRNA的生物发生。这项工作为HCC治疗提供了有希望的先导化合物,突出了基于miRNA的疗法对人类癌症的治疗潜力。